Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
about
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic HyperplasiaMinimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology updateMinimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies.Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectivesPhospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.Treatment of lower urinary tract symptoms: agents for intraprostatic injection.Investigational therapies targeted to the treatment of benign prostatic hyperplasia.Targeting kallikrein-related peptidases in prostate cancer.Targeted prodrug approaches for hormone refractory prostate cancer.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.New intraprostatic injectables and prostatic urethral lift for male LUTS.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Effect of transurethral split of the prostate using a double-columnar balloon catheter for benign prostatic hyperplasia: A single-center experience of 565 consecutive patients.Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer.Emerging drugs for the treatment of benign prostatic hyperplasia.Clinical evaluation of embolization of the superior vesical prostatic artery for treatment of benign prostatic hyperplasia: a single-center retrospective study.PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer.
P2860
Q26741226-838CA7E3-DB9D-4531-96A5-7295C924587EQ26796381-5E0FF055-922A-4327-81CA-82A64D745B3DQ33739120-47B2A545-9D16-40EC-B780-7FB0765FFDA0Q34037014-6A31E46A-B1D5-4959-BA1B-D93EB4E42DDFQ36133212-FAC31314-4448-47A8-AD59-8F3924D57BDBQ36243031-21951AEC-D934-43C9-AF55-C9EA074DC049Q36776738-23BE43CF-2E07-4BE2-BC46-D5666E64A4E5Q37088315-34217D92-0B49-4CE3-8FB4-6FA19229B3ECQ38071100-1F8851A3-AEDC-4447-8F02-B953183848FFQ38073830-58964F4E-8031-48EF-84A9-6814E161A1F0Q38191293-28241FE1-80B7-424D-8F56-78DDFED27B2BQ38295983-2F1FBE35-D4F6-4045-9105-F9497C455F13Q38413737-927E825C-B3C1-4F74-B118-B98FDA46F664Q38485721-44D24155-11DE-4B51-831B-E13F9384C38AQ38551294-7956A384-50B8-4C7F-A99F-72CF79FFAE7EQ38760061-2B5DC968-DD0F-4D86-8F33-241A7A1D09E9Q39282111-EE778955-5D4B-41F2-9E25-ED4F2496CC31Q42072059-3DFE6632-B9FD-4B3E-AE9F-AD6E54790EE5Q47553287-73742517-72B2-4140-AFAC-0F8A3A0F1F44Q48513153-58B49E3F-61DE-4921-BE10-634990281459Q55018508-D590F7B3-04EA-48C1-9DDD-8E3FA23CEDF4
P2860
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@ast
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@en
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@nl
type
label
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@ast
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@en
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@nl
prefLabel
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@ast
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@en
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@nl
P2093
P2860
P3181
P1433
P1476
Phase 1 and 2 studies demonstr ...... o benign prostatic hyperplasia
@en
P2093
Blair Egerdie
Gary Steinhoff
Peter Pommerville
Rosemina Merchant
Samuel R Denmeade
P2860
P304
P3181
P356
10.1016/J.EURURO.2010.11.024
P407
P577
2010-11-24T00:00:00Z